2025年第三次临时 股东会 会议资料 会 议 时 间 ： 2025年 12月 16日 2 0 2 5 年 第 三 次 临 时 股 东 会 资 料 2025年第三次临时股东会议程 议案 3、审议《关于修订<董事会议事规则>的议案》。 1 一、主持人宣布会议开始，致欢迎词 二、宣读参会须知 三、会议审议事项 议案 1、审议《关于拟变更公司名称并修订<公司章程>的议案》； 议案 2、审议《关于修订<股东会议事规则>的议案》； 四、报告现场会议到会股东及代表股权情况，宣布投票表决程序，对所审议案进行表 决 五、股东与公司董事、高级管理人员交流 六、总监票人宣布表决结果 七、见证律师宣读法律意见书 八、主持人宣布会议结束 2 0 2 5 年 第 二 次 临 时 股 东 会 资 料 股东参会须知 各位股东： 本次股东会采取现场投票和网络投票相结合的方式召开。 网络投票的流程和方法请参照公司 2025 年 11 月 27 日刊登在《中国证券报》《证 券时报》《上海证券报》和巨潮资讯网（www.cninfo.com.cn）上的《关于召开 2025 年第三次临时股东会的通知》中的附件一"参加网络投票的具体操作流程"进行投票。 ...

证券代码：000590 证券简称：启迪药业 公告编号：2025-059 启迪药业集团股份公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上 市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等 法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 12 月 16 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 12 月 16 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的 具体时间为 2025 年 12 月 16 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025 年 12 ...

证券代码：000590 证券简称：启迪药业 公告编号：2025-057 启迪药业集团股份公司 第十届董事会临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 启迪药业集团股份公司（以下简称"公司"）第十届董事会临时会议通知于 2025 年 11 月 21 日通过电子邮件的方式发出。会议于 2025 年 11 月 25 日以现场 与通讯相结合方式召开。会议由董事长江琎先生主持，会议应出席董事 7 人，实 际参加表决董事 7 人，其中以通讯方式表决 1 人，无委托出席情况。公司高级管 理人员列席了会议，会议的召开、表决程序符合《公司法》及《公司章程》的规 定。会议经过充分讨论与审议形成如下决议： 补选后的委员组成为： 委员名单：罗怀青、黄文表、雷振华； 主任委员：罗怀青。 表决结果：7 票赞成，0 票反对，0 票弃权。 三、通过《关于补选公司董事会薪酬与考核委员会委员的议案》； 一、通过《关于补选公司董事会战略委员会委员的议案》； 公司董事会提名补选罗怀青先生为董事会战略委员会委员。 补选后的委员组成为： 委员名单：江琎、倪小桥、周延奇、罗怀青、黄文 ...

Core Viewpoint - Qidi Pharmaceutical has shown a significant stock price increase of 62.59% year-to-date, despite recent declines in the short term [1][2] Financial Performance - As of September 30, Qidi Pharmaceutical reported a revenue of 225 million yuan, representing a year-on-year growth of 3.97% [2] - The company experienced a net profit loss of 14.82 million yuan, but this reflects a year-on-year improvement of 47.91% [2] - The company has cumulatively distributed dividends of 97.39 million yuan since its A-share listing, with no dividends paid in the last three years [3] Stock Market Activity - On November 25, Qidi Pharmaceutical's stock price rose by 2.03%, reaching 11.56 yuan per share, with a trading volume of 15.03 million yuan [1] - The stock has seen a net inflow of 584,800 yuan from main funds, with large orders accounting for 17.62% of total purchases [1] - The company has appeared on the stock market's "Dragon and Tiger List" three times this year, with the most recent instance on July 16, where it recorded a net buy of -44.09 million yuan [1] Company Overview - Qidi Pharmaceutical, established on November 12, 1993, and listed on January 19, 1996, is based in Hunan Province and specializes in traditional Chinese medicine and Western pharmaceutical formulations [2] - The company's main business revenue composition includes 79.43% from traditional Chinese medicine products, 14.28% from Guangdong Xiantong products, and 5.98% from other sources [2] - The company operates within the pharmaceutical and biotechnology sector, focusing on traditional Chinese medicine [2]

Macro Strategy - Recent international gold prices are fluctuating at high levels, with domestic jewelry gold prices also remaining elevated. There is a new trend in gold consumption favoring lighter products like gold bars. Short-term gold prices are expected to maintain high volatility. Consumers should pay attention to international gold price fluctuations if investing, and choose purchasing timing based on their budget for wearing needs [2][3] - From January to October, the national general public budget revenue reached 18.649 trillion yuan, a year-on-year increase of 0.8%. The national general public budget expenditure was 22.5825 trillion yuan, a year-on-year increase of 2%. Securities transaction stamp duty revenue was 162.9 billion yuan, a year-on-year increase of 88.1% [2] - By the end of 2024, the total asset scale of urban commercial banks in China is projected to be 60.15 trillion yuan, a 134-fold increase since 1995, accounting for 13.53% of the banking financial institutions, with a market share increase of 8.24 percentage points. The non-performing loan ratio is 1.76%, and the provision coverage ratio is 188.08% [2] Industry and Company Medical Services Industry - The medical and biological sector rose by 3.29%, ranking fifth among the 31 first-level industries. The Shanghai and Shenzhen 300 Index fell by 1.08%, indicating that the medical sector outperformed the index by 4.37 percentage points [6] - The PE (ttm) of the medical services sector is 33.47X, with a PB (lf) of 3.37X. The PE increased by 0.51X and the PB increased by 0.05X compared to the previous week [7][8] - The TIDES CRDMO market is expected to grow significantly, with the global market projected to increase from 2.1 billion USD in 2018 to 5.5 billion USD in 2023, with a CAGR of 20.9%, and further to 37.3 billion USD by 2032, with a CAGR of 23.8%. The Chinese market is expected to grow from 200 million USD in 2018 to 800 million USD in 2023, with a CAGR of 37.1%, and to 6.2 billion USD by 2032, with a CAGR of 25.5% [9] - Investment recommendations for the medical services sector include focusing on high-growth companies in the ADC CDMO and TIDES CDMO areas, as well as companies in the third-party testing laboratories and consumer medical sectors [10] Traditional Chinese Medicine Industry - The traditional Chinese medicine sector rose by 4.08%, ranking third among secondary sub-sectors. Companies such as Te Yi Pharmaceutical and Zhongsheng Pharmaceutical performed well, while others like *ST Changyao and ST Huluwa performed poorly [12] - The PE (ttm) for the traditional Chinese medicine sector is 29.25X, with a PB (lf) of 2.47X, indicating a slight increase from the previous week [13][14] - The market for traditional Chinese medicinal materials is experiencing volatility, with an overall supply surplus due to increased arrivals from new harvests. Recent weather conditions have also impacted harvesting [15] - The steady advancement of centralized procurement in the traditional Chinese medicine industry aims to reduce patient medication costs and shift competition towards cost control and quality standards [16][17] - Investment recommendations for the traditional Chinese medicine sector include focusing on companies with competitive advantages in product quality and cost, as well as those benefiting from national reforms and centralized procurement policies [18][19]

启迪药业集团股份公司 （经公司2025年第二次临时股东会审议通过） | 第十章 | 合并、分立、增资、减资、解散和清算 39 | | | --- | --- | --- | | 第一节 | 合并、分立、增资和减资 39 | | | 第二节 | 解散和清算 | 40 | | 第十一章 | 修改章程 | 42 | | 第十二章 | 附则 | 42 | 第一章 总则 第三条 公司于 1995 年 12 月 25 日经中国证券监督管理委员会（以下简称"中国证 监会"）批准，首次向社会公众发行人民币普通股 1,500 万股(含内部职工股 500 万股)， 于 1996 年 1 月 19 日在深圳证券交易所上市。 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和行为， 充分发挥中国共产党在公司的领导核心作用，根据《中华人民共和国公司法》(以下简 称《公司法》)、《中华人民共和国证券法》(以下简称《证券法》)、《中国共产党章程》 （以下简称《党章》）和其他有关规定，制定本章程。 第四条 公司注册名称： 中文全称：启迪药业集团股份公司 | 第一章 | 总则 | 3 | | --- | --- | --- | ...

证券代码：000590 证券简称：启迪药业 公告编号：2025-056 启迪药业集团股份公司 2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 假记载、误导性陈述或重大遗漏。 记载、误导性陈述或重大遗漏。 特别提示 1、本次会议未出现否决提案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 6、会议的召开符合《公司法》《股票上市规则》《上市公司股东大会规范 意见》及公司章程的规定。2025年10月28日，公司召开了第十届董事会临时会议， 审议通过了《关于召开2025年第二次临时股东大会的议案》。本次会议的通知刊 登于2025年10月30日《中国证券报》《证券时报》《上海证券报》和巨潮资讯网 一、会议召开的情况 1、召开时间： （1）现场会议时间：2025 年 11 月 18 日(星期二)下午 14:30。 （2）网络投票时间：2025 年 11 月 18 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为 2025 年 11 月 18 日上午 9:15—9:25,9: ...

湖南启元律师事务所 关于 启迪药业集团股份公司 2025年第二次临时股东大会的 法律意见书 二〇二五年十一月 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410005 电话：（0731）82953-778 传真：（0731）82953-779 网站：www.qiyuan.com 1、刊登在中国证券监督管理委员会（以下简称"中国证监会"）指定媒体 和巨潮咨询网站（http://www.cninfo.com.cn/）的与本次股东大会有关的通知等公 告事项； 2、出席会议的股东或其代理人的身份证明文件、持股证明文件、授权委托 书等； 致：启迪药业集团股份公司 湖南启元律师事务所（以下简称"本所"）受启迪药业集团股份公司（以下 简称"公司"）委托，指派本所律师出席了公司 2025 年第二次临时股东大会（以 下简称"本次股东大会"），对本次股东大会的召集和召开程序、出席会议人员 及召集人的资格、表决程序和表决结果的合法有效性进行现场律师见证，并发表 本法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》（ ...

Group 1 - A total of 18 stocks experienced a price increase of over 40% during the week of November 10 to November 14, with 11 stocks rising over 50% [1] - Huasheng Lithium Battery topped the weekly gainers with a remarkable increase of 79.61% [1] - Other notable gainers included Haike Xinyuan, Jindike, and Furui Shares, with weekly increases of 71.38%, 61.65%, and 61.23% respectively [1] Group 2 - On the downside, 5 stocks recorded a decline of over 20% during the same week, with *ST Changyao leading the losses at 33.62% [1] - Haitan Shares and Degute experienced declines of 29.01% and 24.65% respectively [1]

Core Viewpoint - Regulatory authorities have intensified their crackdown on illegal activities by listed companies, with 60 companies under investigation this year, primarily for information disclosure violations and some for financial fraud [1][2]. Group 1: Investigation and Violations - As of November 11, 2023, 60 A-share companies have been investigated, with 90% of these cases related to information disclosure violations [2]. - Notable companies under investigation include *ST Changyao and *ST Dongtong, with the latter facing a forced delisting due to significant financial discrepancies [2]. - The majority of the investigated companies have poor fundamentals, with nearly 70% reporting net losses in the first three quarters of the year [2]. Group 2: Financial Penalties and Consequences - Companies found guilty of violations may face administrative penalties up to 10 million yuan, and severe cases could lead to criminal charges [3]. - Companies and their executives may also be liable for civil compensation to investors due to securities fraud, as stipulated by the Securities Law [2][3]. Group 3: Market Impact - The stock prices of companies under investigation have significantly declined, with *ST Changyao and *ST Dongtong experiencing trading halts following their announcements of investigations [1].